Inhibition of respiratory viruses by nasally administered siRNA
- PMID: 15619632
- DOI: 10.1038/nm1164
Inhibition of respiratory viruses by nasally administered siRNA
Abstract
Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens of paramount medical significance that exert high mortality. At present, there is no reliable vaccine or antiviral drug against either virus. Using an RNA interference (RNAi) approach, we show that individual as well as joint infection by RSV and PIV can be specifically prevented and inhibited by short interfering RNAs (siRNAs), instilled intranasally in the mouse, with or without transfection reagents. The degree of protection matched the antiviral activity of the siRNA in cell culture, allowing an avenue for quick screening of an efficacious siRNA. When targeting both viruses in a joint infection, excess of one siRNA moderated the inhibitory effect of the other, suggesting competition for the RNAi machinery. Our results suggest that, if properly designed, low dosages of inhaled siRNA might offer a fast, potent and easily administrable antiviral regimen against respiratory viral diseases in humans.
Similar articles
-
Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene.Nat Med. 2005 Jan;11(1):56-62. doi: 10.1038/nm1174. Epub 2004 Dec 26. Nat Med. 2005. PMID: 15619625
-
RNA interference strategies as therapy for respiratory viral infections.Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S118-22. doi: 10.1097/INF.0b013e318168b759. Pediatr Infect Dis J. 2008. PMID: 18820571
-
Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin.Antiviral Res. 2004 Mar;61(3):195-206. doi: 10.1016/j.antiviral.2003.10.005. Antiviral Res. 2004. PMID: 15168801
-
Control of nonsegmented negative-strand RNA virus replication by siRNA.Virus Res. 2004 Jun 1;102(1):27-35. doi: 10.1016/j.virusres.2004.01.012. Virus Res. 2004. PMID: 15068877 Review.
-
The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses.Antivir Ther. 2012;17(1 Pt B):213-25. doi: 10.3851/IMP2064. Epub 2012 Feb 3. Antivir Ther. 2012. PMID: 22311654 Review.
Cited by
-
Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review.Front Microbiol. 2024 Jun 13;15:1393646. doi: 10.3389/fmicb.2024.1393646. eCollection 2024. Front Microbiol. 2024. PMID: 38939184 Free PMC article. Review.
-
Stability of Naked Nucleic Acids under Physical Treatment and Powder Formation: Suitability for Development as Dry Powder Formulations for Inhalation.Pharmaceutics. 2023 Dec 16;15(12):2786. doi: 10.3390/pharmaceutics15122786. Pharmaceutics. 2023. PMID: 38140126 Free PMC article.
-
Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment.Asian J Pharm Sci. 2023 Sep;18(5):100852. doi: 10.1016/j.ajps.2023.100852. Epub 2023 Oct 10. Asian J Pharm Sci. 2023. PMID: 37920650 Free PMC article. Review.
-
Cryo-EM structure of the nucleocapsid-like assembly of respiratory syncytial virus.Signal Transduct Target Ther. 2023 Aug 22;8(1):323. doi: 10.1038/s41392-023-01602-5. Signal Transduct Target Ther. 2023. PMID: 37607909 Free PMC article.
-
Where should siRNAs go: applicable organs for siRNA drugs.Exp Mol Med. 2023 Jul;55(7):1283-1292. doi: 10.1038/s12276-023-00998-y. Epub 2023 Jul 10. Exp Mol Med. 2023. PMID: 37430086 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
